APA (7th ed.) Citation

Ella, R., Reddy, S., Blackwelder, W., Potdar, V., Yadav, P., Sarangi, V., . . . Waghmare, S. (2021). Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomised, double-blind, controlled, phase 3 trial. The Lancet (British edition), 398(10317), 2173-2184. https://doi.org/10.1016/S0140-6736(21)02000-6

Chicago Style (17th ed.) Citation

Ella, Raches, et al. "Efficacy, Safety, and Lot-to-lot Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (BBV152): Interim Results of a Randomised, Double-blind, Controlled, Phase 3 Trial." The Lancet (British Edition) 398, no. 10317 (2021): 2173-2184. https://doi.org/10.1016/S0140-6736(21)02000-6.

MLA (9th ed.) Citation

Ella, Raches, et al. "Efficacy, Safety, and Lot-to-lot Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (BBV152): Interim Results of a Randomised, Double-blind, Controlled, Phase 3 Trial." The Lancet (British Edition), vol. 398, no. 10317, 2021, pp. 2173-2184, https://doi.org/10.1016/S0140-6736(21)02000-6.